Oral iron absorption test in patients on CAPD: comparison of ferrous sulfate and a polysaccharide ferric complex.
We prospectively compared the absorption of ferrous sulfate to that of a polysaccharide ferric complex (Niferex) in 5 healthy controls and 7 stable patients on continuous ambulatory peritoneal dialysis (CAPD). All study subjects received an equivalent of 150 mg of elemental iron of either preparation, in a random fashion. After a baseline fasting serum iron level was obtained, the serum iron concentration was measured at 2 h in the control group and at 2 and 4 h in the CAPD patients. One to 2 months later, all study subjects received the alternative iron compound and were studied in an identical manner. A significant rise in serum iron was only observed in the healthy subjects after the ingestion of ferrous sulfate and not Niferex (ferrous sulfate 102 +/- (SE) 9 vs. 142 +/- 7 Mg/dl, p = 0.0005; Niferex 96 +/- (SE) 10 vs. 102 +/- 12 mg/dl; baseline vs. 2 h, respectively). The absorption of both compounds was poor in the patients on CAPD, with the 2- and 4-hour serum iron levels not significantly higher than the baseline values (ferrous sulfate 73 +/- 7 vs. 107 +/- 21 vs. 109 +/- 21 mg/dl, p = NS; Niferex 57 +/- 11 vs. 65 +/- 14 vs. 60 +/- 11 mg/dl, p = NS; baseline vs. 2 vs. 4 h, respectively). Our data suggest that the absorption of both ferrous sulfate and ferric polysaccharide complex is poor in patients on CAPD.
Division of Nephrology, St. Louis University Health Sciences Center, Mo 63110, USA.
M
M
Tinawi
K J
KJ
Martin
B
B
Bastani
D000284:Administration, Oral; D000328:Adult; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D005296:Ferrous Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D007408:Intestinal Absorption; D007501:Iron / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D011134:Polysaccharides / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use; D012016:Reference Values; D013997:Time Factors
D005296:Ferrous Compounds; D011134:Polysaccharides; D011994:Recombinant Proteins; D004921:Erythropoietin; C020748:ferrous sulfate; C078972:Niferex; D007501:Iron